CAJ | 학술논문

三阴性乳腺癌缺乏ER、PR及Her2受体的表达,现有的内分泌治疗和分子靶向治疗无法应用.相较于其他分子类型的乳腺癌,三阴性乳腺癌的复发率、转移率及病死率仍较高.除发掘更有效的化疗药物及方案外,研究对三阴性乳腺癌有效的分子靶向治疗药物也至关重要.目前已开发出针对不同靶点的靶向药物主要包括以贝伐单抗为代表的抗血管生成药物,以希妥昔单抗和帕尼单抗为代表的抗表皮生长因子受体药物及以iniparib、olaparib和veliparib为代表的PARP抑制剂.虽然这些药物在细胞实验和动物模型研究中都表现出出色的抗肿瘤活性,它们在临床试验中的疗效却不甚理想.本文将就近年三阴性乳腺癌分子靶向治疗研究的不同分子靶点及相应的分子靶向药物临床应用的研究上取得的进展做一综述.
삼음성유선암결핍ER、PR급Her2수체적표체,현유적내분비치료화분자파향치료무법응용.상교우기타분자류형적유선암,삼음성유선암적복발솔、전이솔급병사솔잉교고.제발굴경유효적화료약물급방안외,연구대삼음성유선암유효적분자파향치료약물야지관중요.목전이개발출침대불동파점적파향약물주요포괄이패벌단항위대표적항혈관생성약물,이희타석단항화파니단항위대표적항표피생장인자수체약물급이iniparib、olaparib화veliparib위대표적PARP억제제.수연저사약물재세포실험화동물모형연구중도표현출출색적항종류활성,타문재림상시험중적료효각불심이상.본문장취근년삼음성유선암분자파향치료연구적불동분자파점급상응적분자파향약물림상응용적연구상취득적진전주일종술.
Triple negative breast cancer (TNBC) is characterized by lack of expression of the estrogen (ER)and progesterone receptors (PRs) and the human epidermal growth factor receptor (HER-2) that are commonly observed in other breast cancer subtypes.Treatment options are limited since the hormonal receptor and HER-2 antagonists are ineffective for TNBC.In contrast to non-TNBC,TNBC is more aggressive with higher recurrence,metastatic,and mortality rates.Besides further studies on cytotoxic drugs and chemotherapy regimens,More studies on potential targeted molecular treatment of TNBC should be strengthened.For the moment,potential targeted molecular treatment of TNBC including antiangiogenic agents,epidermal growth factor receptor (EGFR) inhibitors and poly (adenosine diphosphate ribose) polymerase (PARP).In contrast to their surprising anti-tumor effectivness in basic experiments,these targeted molecular agents show no promising results in clinical trials by now.This article aims to review advancements of targeted molecular treatment of TNBC in recent years.